Patricia Inácio, PhD,  science writer—

Levels of NT-proBNP can predict long-term outcomes and response to treatment with Uptravi (selexipag) in patients with pulmonary arterial hypertension (PAH), a post-hoc analysis of the Phase 3 GRIPHON trial shows. The study, “Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III…

Despite having better heart function and less severe disease, patients with a lung disease underlying their pulmonary hypertension (PH) have survival rates that are as poor as those with idiopathic PH, a study suggests. The study, “Outcomes of Lung Disease-Associated Pulmonary Hypertension and Impact of Elevated Pulmonary Vascular Resistance,”…

United Therapeutics announced it has ended its Phase 3 BEAT trial testing esuberaprost as an add-on therapy to its product Tyvaso (inhaled treprostinil) for clinically symptomatic patients with pulmonary arterial hypertension (PAH). According to a company press release, the study failed to reach its main endpoint of delaying the…

Mutations in the BMPR2 gene alter the ratio of pro- and anti-death signals in cells lining the blood vessels, promoting cells destined to die to escape, which in turn culminates in a build-up of cells in blood vessels and their subsequent blockage, leading to pulmonary arterial hypertension (PAH). The factor mediating this resistance to…

People with polysplenia syndrome — a condition characterized by a “left-sidedness” on both sides of the body — have an increased risk for early development of pulmonary hypertension (PH), a Japanese study suggests. The study, titled “Polysplenia Syndrome as a Risk Factor for Early Progression of Pulmonary Hypertension,” was…

Estrogen, one of the major female sex hormones, has a protective effect in pulmonary arterial hypertension (PAH) by halting oxidative stress and collagen deposition, a rat study suggests. The study, “Effect of estrogen on right ventricular remodeling of monocrotaline-induced pulmonary arterial hypertension in rats and its mechanism,” was…

High pulmonary pressure, cardiac medication use, and poor heart function are all risk factors for pulmonary hypertension (PH) in adults after a procedure to repair an atrial septal defect, a hole in the wall (septum) that divides the two upper chambers of the heart, a study reports. The study,…

Repeated measurements of different biomarkers over time offer a better risk prediction than single measurements for pulmonary arterial hypertension (PAH) associated with congenital heart disease, a study reports. The study, “Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease,” was published in…

Genetic variants close to the SOX17 and the HLA-DPB1 genes are linked to pulmonary arterial hypertension (PAH), according to the findings of the largest genetic study to date in PAH patients. The study, “Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis,” was published in the…

Pulmonary arterial hypertension (PAH) patients with an enlarged right side of the heart show higher pulmonary arterial pressures and increased resistance to blood flow compared to healthy controls, a new study reports. The study “Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a…

The severity of pulmonary hypertension (PH) increases the risk of fetus death, although mortality among PH pregnant women is low, according to a Chinese review study. The study, “Pregnancy and pulmonary hypertension: An exploratory analysis of risk factors and outcomes” was published in the journal Medicine. Pregnancy induces…

Idiopathic pulmonary arterial hypertension (IPAH) patients who failed to respond to treatment with Revatio (sildenafil), either alone or combined with other phosphodiesterase type 5 inhibitors, may benefit by switching to Adempas (riociguat), according to results of a pilot study. Adempas was also seen to ably help treatment-naive patients, using it as a first…